Medtronic plc
No SEC Form 4 filings for $MDT in the last 30 days.
Medtronic said its Sphere-9 catheter with Affera mapping and ablation system received a CE mark in Europe for ventricular arrhythmia treatment. The system previously had CE for atrial arrhythmias (initially March 2023) and FDA clearance for the same (October 2024). Medtronic is also running a US trial and seeking FDA clearance.
Medtronic plc (MDT) said it received an expanded CE Mark indication in Europe for its Affera Mapping and Ablation System with the Sphere-9 Catheter to treat ventricular arrhythmias, including ventricular tachycardia, according to the company. The update relates to the system’s approved use in the EU.
Medtronic (NYSE: MDT) said it expanded the CE Mark indication for its Affera Mapping and Ablation System with the Sphere-9 catheter to treat ventricular arrhythmias, including ventricular tachycardia and PVCs. Medtronic also reported FDA Breakthrough Device Designation for Sphere-9 and that the U.S. Sphere VT pivotal trial is enrolling patients.
Over the past 7 days, alphai's AI scored 11 news stories mentioning MDT (Medtronic plc). Coverage has skewed bearish: 4 bullish, 0 neutral, and 7 bearish.
Recent MDT coverage spans financial news and regulation.
The CE mark expansion broadens eligible ventricular arrhythmia patients in Europe and supports a larger commercial addressable market while Medtronic continues FDA efforts.
Expanded CE Mark scope can broaden eligible patient use in Europe, supporting incremental demand for Affera procedures.
CE Mark expansion plus FDA Breakthrough Device Designation and ongoing U.S. pivotal enrollment increases commercialization and approval optionality for Sphere-9 in ventricular arrhythmias.
Street sentiment is turning more bullish for MDT based on a specific analyst upgrade and price-target range.
The verdict increases litigation and reputational risk for Medtronic’s hernia mesh exposure via Covidien, potentially pressuring future settlements and liability estimates.
alphai scores every news story that mentions MDT with an AI model for sentiment and relevance, and aggregates insider trades from Medtronic plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Medtronic said its Sphere-9 catheter with Affera mapping and ablation system received a CE mark in Europe for ventricular arrhythmia treatment. The system previously had CE for atrial arrhythmias (initially March 2023) and FDA clearance for the same (October 2024). Medtronic is also running a US trial and seeking FDA clearance.
4 min readMedtronic plc (MDT) said it received an expanded CE Mark indication in Europe for its Affera Mapping and Ablation System with the Sphere-9 Catheter to treat ventricular arrhythmias, including ventricular tachycardia, according to the company. The update relates to the system’s approved use in the EU.
2 min readMedtronic (NYSE: MDT) said it expanded the CE Mark indication for its Affera Mapping and Ablation System with the Sphere-9 catheter to treat ventricular arrhythmias, including ventricular tachycardia and PVCs. Medtronic also reported FDA Breakthrough Device Designation for Sphere-9 and that the U.S. Sphere VT pivotal trial is enrolling patients.
4 min readAnalysts covering Medtronic (MDT) expect fiscal-year EPS for the year ending April 2027 to rise 7.4% to $5.94. The stock has beaten consensus EPS in each of the last four quarters. Of 29 analysts, consensus is “Moderate Buy” with 15 “Strong Buy” ratings. UBS upgraded MDT to “Buy” with a $100 target; mean target is $96.81 and Street-high is $120.
2 min readA federal jury in Massachusetts awarded Alabama couple Larry and Tammy Patterson $88 million in a hernia mesh case against Covidien, a Medtronic subsidiary. The jury found Covidien failed to adequately warn about risks of its Symbotex mesh. Larry received $77 million and Tammy $11 million. The verdict was the first federal bellwether in a multidistrict litigation with over 2,500 pending suits.
4 min readA federal jury ordered Medtronic to pay $88 million to an Alabama man and his wife in the first hernia mesh test trial. The case alleged Medtronic’s Covidien division failed to warn about risks of its Symbotex implanted mesh used in 2017. Medtronic said it will seek post-trial relief and appeal, while about 10,350 plaintiffs remain in similar litigation.
4 min readA federal jury ordered Medtronic (NYSE:MDT) to pay $88 million to an Alabama couple in the first hernia mesh trial tied to implants made by its Covidien unit. The jury found Covidien failed to adequately warn of risks, and no punitive damages or fraud were awarded. Medtronic said it will seek post-trial motions and appeal.
3 min readReuters reports Medtronic was ordered to pay $88 million in a bellwether hernia mesh lawsuit. The plaintiff alleged bowel adhesions after use of Covidien Symbotex mesh and required revision surgery. Reuters says this was the first trial among thousands, with about 2,500 similar Covidien hernia mesh cases pending in federal MDL.
2 min readA US jury found Medtronic liable for $88 million in the first case involving Covidien hernia mesh, according to the report. The matter will proceed to trial for additional issues, with the outcome potentially affecting Medtronic’s legal costs and related financial exposure.
1 min readA US jury ordered Medtronic to pay $88 million in the first trial case related to Covidien’s hernia mesh, Reuters reported. The case will proceed to trial over alleged claims tied to the product. The ruling is a potential liability datapoint for Medtronic investors.
2 min read
